To overcome these limitations, we used a BAb directed against CEA and human TNFα to target this cytokine to the human pancreatic carcinoma cells BxPC-3 treated simultaneously with RT. This evidence concerns the gene CEACAM5 and exocrine pancreatic carcinoma.